Mutual effect between neuropeptides and inflammatory cytokines in neurogenic SMSCs of human temporomandibular joint

Abstract

In temporomandibular disorders (TMD), pain takes place when neuropeptides stimulate synovial tissue to produce several cytokines such as interleukin (IL)-1β, IL-6 and tumor necrosis factor (TNF)-α, which activate neurons and glia of synovial membrane at the bilaminar regions of temporomandibular joint (TMJ). It has been reported that, after neurogenic differentiation, the synovial mesenchymal stem cells (SMSCs), deriving from TMJ, possess the same cytological features as the neuronal cells. This study examined the ability of substance P (SP) and calcitonin gene-related peptide (CGRP) to stimulate SMSCs and neurogenic SMSCs secreting inflammatory cytokines during TMD, evaluated the mutual effects of inflammatory cytokines and neuropeptides and tested the analgesic effect of hyaluronic acid (HA). The levels of IL-1β, IL-6 and TNF-α in SMSCs and neurogenic SMSCs in the presence of neuropeptides were measured by ELISA. SP and CGRP produced by SMSCs and neurogenic SMSCs were determined by RT-PCR and Western blotting. The results showed that the expression of SP and CGRP was significantly enhanced in the neurogenic SMSCs in response to IL-1β, IL-6 and TNF-α, and the effect was remarkably inhibited by HA. IL-1β, IL-6 and TNF-α, in return, could be enhanced in the neurogenic SMSCs upon stimulation by SP and CGRP. Neuropeptides and inflammatory cytokines might work mutually on the TMD pain. The HA-mediated analgesic effect may be implicated in the inhibition of SP and CGRP expression in neurogenic SMSCs.

Keywords

hyaluronic acid / inflammatory cytokines / substance P / calcitonin gene-related peptide / neurogenesis / temporomandibular disorders

References

[1] MadlandG, FeinmannC, NewmanS. Factors associated with anxiety and depression in facial arthromyalgia. Pain, 2000, 84(2–3): 225-232

[2] IvanusicJJ, BeainiD, HatchRJ, et al.. Peripheral N-methyl-d-aspartate receptors contribute to mechanical hypersensitivity in a rat model of inflammatory temporomandibular joint pain. Eur J Pain, 2011, 15(2): 179-185

[3] SteedPA, WexlerGB. Temporomandibular disorders-traumatic etiology vs. nontraumatic etiology: a clinical and methodological inquiry into symptomatology and treatment outcomes. Cranio, 2001, 19(3): 188-194

[4] SatoJ, SegamiN, KaneyamaK, et al.. Relationship of calcitonin gene-related peptide in synovial tissues and temporomandibular joint pain in humans. Oral Surg Oral Med Oral Pathol Oral Radiol Endod, 2004, 98(5): 533-540

[5] SatoJ, SegamiN, YoshitakeY, et al.. Specific expression of substance P in synovial tissues of patients with symptomatic, non-reducing internal derangement of the temporomandibular joint: comparison with clinical findings. Br J Oral Maxillofac Surg, 2007, 45(5): 372-377

[6] LiuZ, ZhangZ. Research progress of repair of the perforation of the disk of temporomandibular joint. J Clin Stomatol (Chinese), 2013, 29(10): 635-637

[7] CadyRJ, GlennJR, SmithKM, et al.. Calcitonin gene-related peptide promotes cellular changes in trigeminal neurons and glia implicated in peripheral and central sensitization. Mol Pain, 2011, 7: 94

[8] LiuZ, LongX. Research progress of embryonic stem cells differentiation into neural stem cells. Int J Oral Med, 2009, 36(06): 672-674

[9] LiuZ, LongX, LiJ, et al.. Differentiation of temporomandibular joint synovial mesenchymal stem cells into neuronal cells in vitro: an in vitro study. Cell Biol Int, 2011, 35(1): 87-91

[10] Balkowiec-IskraE. The role of immune system in inflammatory pain pathophysiology. Pol Merkur Lekarski, 2010, 29(174): 395-399

[11] LaiYC, ShaftelSS, MillerJN, et al.. Intraarticular induction of interleukin-1beta expression in the adult mouse, with resultant temporomandibular joint pathologic changes, dysfunction, and pain. Arthritis Rheum, 2006, 54(4): 1184-1197

[12] JorgensenC, SanyJ. Modulation of the immune response by the neuro-endocrine axis in rheumatoid arthritis. Clin Exp Rheumatol, 1994, 12(4): 435-441

[13] InoueH, ShimoyamaY, HirabayashiK, et al.. Production of neuropeptide substance P by synovial fibroblasts from patients with rheumatoid arthritis and osteoarthritis. Neurosci Lett, 2001, 303(3): 149-152

[14] HernanzA, MedinaS, de MiguelE, et al.. Effect of calcitonin gene-related peptide, neuropeptide Y, substance P, and vasoactive intestinal peptide on interleukin-1beta, interleukin-6 and tumor necrosis factor-alpha production by peripheral whole blood cells from rheumatoid arthritis and osteoarthritis patients. Regul Pept, 2003, 115(1): 19-24

[15] PuhlW, ScharfP. Intra-articular hyaluronan treatment for osteoarthritis. Ann Rheum Dis, 1997, 56(7): 441

[16] LongX, ChenG, ChengAH, et al.. A randomized controlled trial of superior and inferior temporomandibular joint space injection with hyaluronic acid in treatment of anterior disc displacement without reduction. J Oral Maxillofac Surg, 2009, 67(2): 357-361

[17] CampoGM, AvenosoA, CampoS, et al.. Molecular size hyaluronan differently modulates toll-like receptor-4 in LPS-induced inflammation in mouse chondrocytes. Biochimie, 2009, 92(2): 204-215

[18] LiJ, LongX, KeJ, et al.. Identification and characterization of synovial mesenchymal stem cells in temporomandibular joint. Zhonghua Kou Qiang Yi Xue Za Zhi (Chinese), 2005, 40(5): 362-364

[19] CastellaniML, GalzioRJ, FelacoP T, et al.. VEGF, substance P and stress, new aspects: a revisited study. J Biol Regul Homeost Agents, 2010, 24(3): 229-237

[20] RosenfeldMG, MermodJJ, AmaraSG, et al.. Production of a novel neuropeptide encoded by the calcitonin gene via tissue-specific RNA processing. Nature, 1983, 304(5922): 129-135

[21] BowenEJ, SchmidtTW, FirmCS, et al.. Tumor necrosis factor-alpha stimulation of calcitonin gene-related peptide expression and secretion from rat trigeminal ganglion neurons. J Neurochem, 2006, 96(1): 65-77

[22] KoppS, WennebergB, HaraldsonT, et al.. The short-term effect of intra-articular injections of sodium hyaluronate and corticosteroid on temporomandibular joint pain and dysfunction. J Oral Maxillofac Surg, 1985, 43(6): 429-435

[23] Guarda-NardiniL, FerronatoG, FaveroL, et al.. Predictive factors of hyaluronic acid injections short-term effectiveness for TMJ degenerative joint disease. J Oral Rehabil, 2011, 38(5): 315-320

[24] WeiL, XiongH, LiB, et al.. Change of HA molecular size and boundary lubrication in synovial fluid of patients with temporomandibular disorders. J Oral Rehabil, 2010, 37(4): 271-277

[25] YasudaT. Hyaluronan inhibits prostaglandin E2 production via CD44 in U937 human macrophages. Tohoku J Exp Med, 2010, 220(3): 229-235

[26] GotohS, OnayaJ, AbeM, et al.. Effects of the molecular weight of hyaluronic acid and its action mechanisms on experimental joint pain in rats. Ann Rheum Dis, 1993, 52(11): 817-822

[27] SchimizziAL, MassieJB, MurphyM, et al.. High-molecular-weight hyaluronan inhibits macrophage proliferation and cytokine release in the early wound of a preclinical postlaminectomy rat model. Spine J, 2006, 6(5): 550-556

[28] GranetC, MiossecP. Combination of the pro-inflammatory cytokines IL-1, TNF-alpha and IL-17 leads to enhanced expression and additional recruitment of AP-1 family members, Egr-1 and NF-kappaB in osteoblast-like cells. Cytokine, 2004, 26(4): 169-177

[29] DaiSM, ShanZZ, XuH, et al.. Cellular targets of interleukin-18 in rheumatoid arthritis. Ann Rheum Dis, 2007, 66(11): 1411-1418

[30] FeldmannM, MainiRN. The role of cytokines in the pathogenesis of rheumatoid arthritis. Rheumatology (Oxford), 1999, 38Suppl2: 3-7

[31] ChoiHM, da OhH, BangJS, et al.. Differential effect of IL-1beta and TNFalpha on the production of IL-6, IL-8 and PGE2 in fibroblast-like synoviocytes and THP-1 macrophages. Rheumatol Int, 2010, 30(8): 1025-1033

[32] KaneyamaK, SegamiN, NishimuraM, et al.. Importance of proinflammatory cytokines in synovial fluid from 121 joints with temporomandibular disorders. Br J Oral Maxillofac Surg, 2002, 40(5): 418-423